|
|
 Previous Article | Table of Contents | Next Article 
EDITORIAL
Allogeneic Blood Stem Cell Transplantation: Considerations for Donors
Paolo Anderlini,
Martin Körbling,
David Dale,
Alois Gratwohl,
Norbert Schmitz,
David Stroncek,
Craig Howe,
Susan Leitman,
Mary Horowitz,
Eliane Gluckman,
Scott Rowley,
Donna Przepiorka, and
Richard Champlin
From The University of Texas M.D. Anderson Cancer Center, Houston; University of Washington, Seattle; Kantonsspital, Basel, Switzerland; Christian-Albrechts University, Kiel, Germany for the European Group for Blood and Marrow Transplantation (EBMT); National Marrow Donor Program (NMDP), Minneapolis, MN; the Department of Transfusion Medicine, National Institute of Health Clinical Center, Bethesda, MD, for the NMDP; International Bone Marrow Transplant Registry (IBMTR), Milwaukee, WI; Hopital Saint-Louis, Paris, France; and the The Fred Hutchinson Cancer Research Center, Seattle, WA.
Allogeneic transplantation of cytokine-mobilized peripheral blood stem cells (PBSCs) is now being increasingly performed, but safety considerations for hematologically normal PBSC donors have not been fully addressed. Progenitors are generally mobilized for collection from normal donors using recombinant human granulocyte colony-stimulating factor (rhG-CSF). Although the short-term safety profile of rhG-CSF seems acceptable, experience remains limited and its optimal dose and schedule have not been defined. Minimal data exist regarding long-term safety of rhG-CSF, primarily derived from experience in patients with chronic neutropenia or cancer. An "ad hoc" workshop was recently convened among a group of investigators actively involved in the field of allogeneic stem cell transplantation to discuss the safety issues pertaining to normal PBSC donors. There was agreement on the following points: (1) On the basis of available data, it appears that rhG-CSF treatment and PBSC collection have an acceptable short-term safety profile in normal donors. However, the need for continued safety monitoring was recognized. (2) rhG-CSF doses up to 10 µg/kg/d show a consistent dose-response relationship with the mobilization (and collection) of CD34+ progenitor cells, and this dose is acceptable for routine clinical use. Whether higher doses are superior (or cost effective) remains to be determined, and they may produce more severe side effects. The potential risks of marked leukocytosis (arbitrarily defined as a leukocyte count of more than 70 × 109/L) have been a concern, and rhG-CSF dose reduction is performed by many centers to maintain leukocyte counts below this level. (3) Transient post donation cytopenias, involving granulocytes, lymphocytes, and platelets, may occur and are at least partly related to the leukapheresis procedure. These are generally asymptomatic and self-limited; follow-up blood counts are not necessarily required. Reinfusion of autologous platelet-rich plasma should be considered for donors with expected postdonation thrombocytopenia (platelet count < 80 to 100 × 109/L). (4) Donors should meet the eligibility criteria which apply to donors of apheresis platelets, with the exception that pediatric donors may also be considered. Any deviation from these criteria should have supporting documentation. There is insufficient information at this time to clearly establish definite contraindications for PBSC collection in a hematologically normal donor. Potential contraindications include the presence of inflammatory, autoimmune, or rheumatologic disorders, as well as atherosclerotic or cerebrovascular disease. (5) The creation of an International PBSC Donor Registry is desirable to facilitate monitoring the long-term effects of the procedure. Individual institutions or donor centers are encouraged to establish their own PBSC donor follow-up system, preferably with a standardized approach to data collection.
Blood, Vol. 90 No. 3 (August 1), 1997:
pp. 903-908
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. A. Pulsipher, P. Chitphakdithai, J. P. Miller, B. R. Logan, R. J. King, J. D. Rizzo, S. F. Leitman, P. Anderlini, M. D. Haagenson, S. Kurian, et al.
Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program
Blood,
April 9, 2009;
113(15):
3604 - 3611.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Halter, Y. Kodera, A. U. Ispizua, H. T. Greinix, N. Schmitz, G. Favre, H. Baldomero, D. Niederwieser, J. F. Apperley, A. Gratwohl, et al.
Severe events in donors after allogeneic hematopoietic stem cell donation
Haematologica,
January 1, 2009;
94(1):
94 - 101.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kaptan, C. Beyan, and A. Ifran
Granulocyte colony-stimulating factor.
Can. Med. Assoc. J.,
October 24, 2006;
175(9):
1095 - 1095.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-C. Shyu, S.-Z. Lin, and H. Li
Granulocyte colony-stimulating factor.
Can. Med. Assoc. J.,
October 24, 2006;
175(9):
1095 - 1096.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Ben-Dor, S. Fuchs, and R. Kornowski
Potential Hazards and Technical Considerations Associated With Myocardial Cell Transplantation Protocols for Ischemic Myocardial Syndrome
J. Am. Coll. Cardiol.,
October 17, 2006;
48(8):
1519 - 1526.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Hill, M. A. Syed, A. E. Arai, T. M. Powell, J. D. Paul, G. Zalos, E. J. Read, H. M. Khuu, S. F. Leitman, M. Horne, et al.
Outcomes and Risks of Granulocyte Colony-Stimulating Factor in Patients With Coronary Artery Disease
J. Am. Coll. Cardiol.,
November 1, 2005;
46(9):
1643 - 1648.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. F. Wilson and T. D. Henry
Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor: Double-Edged Swords
J. Am. Coll. Cardiol.,
November 1, 2005;
46(9):
1649 - 1650.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kuramoto, D. A. Follmann, P. Hematti, S. Sellers, B. A. Agricola, M. E. Metzger, R. E. Donahue, C. von Kalle, and C. E. Dunbar
Effect of chronic cytokine therapy on clonal dynamics in nonhuman primates
Blood,
June 1, 2004;
103(11):
4070 - 4077.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Viens, C. Chabannon, P. Pouillard, M. Janvier, W. Brugger, J. Y. Blay, F. Oberling, R. Capdeville, C. Newman, V. Meresse, et al.
Randomized, Controlled, Dose-Range Study of Ro 25-8315 Given Before and After a High-Dose Combination Chemotherapy Regimen in Patients With Metastatic or Recurrent Breast Cancer Patients
J. Clin. Oncol.,
January 1, 2002;
20(1):
24 - 36.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Korbling and P. Anderlini
Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?
Blood,
November 15, 2001;
98(10):
2900 - 2908.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Rowley, G. Donaldson, K. Lilleby, W. I. Bensinger, and F. R. Appelbaum
Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation
Blood,
May 1, 2001;
97(9):
2541 - 2548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Champlin, N. Schmitz, M. M. Horowitz, B. Chapuis, R. Chopra, J. J. Cornelissen, R. P. Gale, J. M. Goldman, F. R. Loberiza Jr, B. Hertenstein, et al.
Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation
Blood,
June 15, 2000;
95(12):
3702 - 3709.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kanamaru, Y. Kawano, T. Watanabe, R. Nakagawa, H. Suzuya, T. Onishi, J. Yamazaki, T. Nakayama, Y. Kuroda, and Y. Takaue
Low Numbers of Megakaryocyte Progenitors in Grafts of Cord Blood Cells May Result in Delayed Platelet Recovery After Cord Blood Cell Transplant
Stem Cells,
May 1, 2000;
18(3):
190 - 195.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. Storek, M. A. Dawson, and D. G. Maloney
Normal T, B, and NK cell counts in healthy donors at 1 year after blood stem cell harvesting
Blood,
May 1, 2000;
95(9):
2993 - 2994.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Blaise, M. Kuentz, C. Fortanier, J. H. Bourhis, N. Milpied, L. Sutton, J.-P. Jouet, M. Attal, P. Bordigoni, J.-Y. Cahn, et al.
Randomized Trial of Bone Marrow Versus Lenograstim-Primed Blood Cell Allogeneic Transplantation in Patients With Early-Stage Leukemia: A Report From the Societe Francaise de Greffe de Moelle
J. Clin. Oncol.,
February 1, 2000;
18(3):
537 - 537.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Engelhardt, H. Bertz, M. Afting, C. F. Waller, and J. Finke
High- Versus Standard-Dose Filgrastim (rhG-CSF) for Mobilization of Peripheral-Blood Progenitor Cells From Allogeneic Donors and CD34+ Immunoselection
J. Clin. Oncol.,
July 1, 1999;
17(7):
2160 - 2160.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Kawano, Y. Takaue, T. Watanabe, T. Abe, Y. Okamoto, A. Iwai, T. Iwai, A. Watanabe, E. Ito, A. Makimoto, et al.
Efficacy of the Mobilization of Peripheral Blood Stem Cells by Granulocyte Colony-Stimulating Factor in Pediatric Donors
Cancer Res.,
July 1, 1999;
59(14):
3321 - 3324.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. H. Eiermann, D. W. van Bekkum, H. M. Vriesendorp, U. Machida, M. Kami, H. Hirai, C. D. Bolan, S. F. Leitman, T. Sasazuki, T. Juji, et al.
Hematopoietic Stem-Cell Transplantation for Acute Leukemia
N. Engl. J. Med.,
March 11, 1999;
340(10):
809 - 812.
[Full Text]
|
|
|
|
|
